Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market capitalization of approximately $80 million, announced today that it has been granted a U.S. patent for AV ...

SOUTH SAN FRANCISCO, Calif., February 05, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for ...

SOUTH SAN FRANCISCO, Calif., March 04, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to ...

In 2019, VistaGen reported that its ketamine-like drug AV-101B failed a phase 2 trial in major depressive disorder (MDD), sending the programme back into early-stage clinical development and ...

SOUTH SAN FRANCISCO, Calif., February 20, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...